Goldman Sachs Upgrades Enbridge (ENB) to Buy
Tweet Send to a FriendGet Alerts ENB Hot Sheet
Price: $46.86 +0.09%
Rating Summary:
7 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 12
Rating Summary:
7 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 12
Trade ENB Now!
Goldman Sachs upgraded Enbridge (NYSE: ENB) (ENB.TO) from Neutral to Buy with a price target of $46.00.
The firm cited: (1) the massive growth in western Canadian and US oil supply, which should drive increased oil infrastructure investments for the industry, (2) ENB.TO's well positioned asset base, which touches multiple key supply sources such as the oil sands/Bakken and demand markets, including the highly strategic Gulf Coast refining complex, and (3) Enbridge's large number of low-risk, fee-based organic growth projects.
For an analyst ratings summary and ratings history on Enbridge click here. For more ratings news on Enbridge click here.
Shares of Enbridge closed at $39.82 yesterday, with a 52 week range of $33.16-$42.06.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm cited: (1) the massive growth in western Canadian and US oil supply, which should drive increased oil infrastructure investments for the industry, (2) ENB.TO's well positioned asset base, which touches multiple key supply sources such as the oil sands/Bakken and demand markets, including the highly strategic Gulf Coast refining complex, and (3) Enbridge's large number of low-risk, fee-based organic growth projects.
For an analyst ratings summary and ratings history on Enbridge click here. For more ratings news on Enbridge click here.
Shares of Enbridge closed at $39.82 yesterday, with a 52 week range of $33.16-$42.06.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Goldman Sachs Upgrades Abbott Labs (ABT) to Buy
- UPDATE: Leerink Swann Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
- CRT Capital Upgrades Northrop Grumman (NOC) to Fairly Valued
Create E-mail Alert Related Categories
UpgradesRelated Entities
Goldman Sachs, Bakken FormationLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

